Site-specific tumor-targeted fluorescent contrast agents

Samuel I. Achilefu; Joseph E. Bugaj; Richard B. Dorshow; Hermo N. Jimenez; Raghavan Rajagopalan; R. Randy Wilhelm; Elizabeth G. Webb; Jack L. Erion

doi:10.1117/12.413736

31 January 2001 Site-specific tumor-targeted fluorescent contrast agents

Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow, Hermo N. Jimenez, Raghavan Rajagopalan, R. Randy Wilhelm, Elizabeth G. Webb, Jack L. Erion

Author Affiliations +

Proceedings Volume 4156, Clinical Lasers and Diagnostics; (2001) https://doi.org/10.1117/12.413736
Event: EOS/SPIE European Biomedical Optics Week, 2000, Amsterdam, Netherlands

Abstract

Site-specific delivery of drugs and contrast agents to tumors protects normal tissues from the cytotoxic effect of drugs, and enhances the contrast between normal and diseased tissues. In optical medicine, biocompatible dyes can be used as photo therapeutics or as contrast agents. Previous studies have shown that the use of covalent or non-covalent dye conjugates of carries such as antibodies, liposomes, and polysaccharides improves the delivery of such molecules to tumors. However, large biomolecules can elicit adverse immunogenic reactions and also result in prolonged blood circulation times, delaying visualization of target tissues. A viable alternative to this strategy is to use small bioactive molecule-dye conjugates. These molecules have several advantages over large biomolecules, including ease of synthesis of a variety of high purity compounds for combinatorial screening of new targets, enhanced diffusivity to solid tumors, and the ability to affect the pharmocokinetics of the conjugates by minor structural changes. Thus, we conjugated a near IR light absorbing dye to bioactive peptides that specifically target over expressed tumor receptors in established rat tumor lines. High tumor uptake of the conjugates was obtained without loss of either the peptide receptor affinity or the dye fluorescence. These findings demonstrate the efficacy of a small peptide-dye conjugate strategy for in vivo tumor imaging. Site-specific delivery of photodynamic therapy agents may also benefit form this approach.

Citation Download Citation

Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow, Hermo N. Jimenez, Raghavan Rajagopalan, R. Randy Wilhelm, Elizabeth G. Webb, and Jack L. Erion "Site-specific tumor-targeted fluorescent contrast agents", Proc. SPIE 4156, Clinical Lasers and Diagnostics, (31 January 2001); https://doi.org/10.1117/12.413736

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available